
    
      This is a single-center trial in subjects with pancreatic cancer and other advanced solid
      tumors. It is an open-label, single arm dose escalation Phase IB trial with subjects accrued
      in a 3 subject dose escalation cohort. Subjects with treated advanced solid tumors, and
      showing disease progression on established standard therapy, will be enrolled in this trial.

      C3 (Simvastatin + Digoxin + Metformin) will be given as three oral pills within recommended
      package insert safe levels. Subjects will be accrued in 3-subject dose escalation cohorts. 3
      additional subjects will be treated at the presumptive maximum effective cohort dose/schedule
      for a total of 6 subjects at maximum effective level.
    
  